Casdin Capital’s MyoKardia, Inc. Common Stock MYOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-870,000
| Closed | -$119M | – | 58 |
|
|
2020
Q3 | $119M | Hold |
870,000
| – | – | 5.31% | 6 |
|
|
2020
Q2 | $84.1M | Sell |
870,000
-125,000
| -13% | -$10.4M | 4.97% | 5 |
|
|
2020
Q1 | $46.6M | Sell |
995,000
-10,000
| -1% | -$641K | 4.95% | 8 |
|
|
2019
Q4 | $73.2M | Sell |
1,005,000
-110,000
| -10% | -$6.67M | 6.74% | 5 |
|
|
2019
Q3 | $58.1M | Sell |
1,115,000
-170,000
| -13% | -$9.04M | 6.02% | 6 |
|
|
2019
Q2 | $64.4M | Hold |
1,285,000
| – | – | 6.03% | 6 |
|
|
2019
Q1 | $66.8M | Buy |
1,285,000
+495,000
| +63% | +$22.8M | 7.34% | 3 |
|
|
2018
Q4 | $38.6M | Sell |
790,000
-15,000
| -2% | -$826K | 6.6% | 2 |
|
|
2018
Q3 | $52.5M | Buy |
805,000
+25,000
| +3% | +$1.47M | 6.38% | 3 |
|
|
2018
Q2 | $38.7M | Buy |
780,000
+220,000
| +39% | +$10.7M | 5.42% | 5 |
|
|
2018
Q1 | $27.3M | Hold |
560,000
| – | – | 4.81% | 9 |
|
|
2017
Q4 | $23.6M | Hold |
560,000
| – | – | 5.74% | 7 |
|
|
2017
Q3 | $24M | Buy |
560,000
+165,000
| +42% | +$5.26M | 6.78% | 2 |
|
|
2017
Q2 | $5.17M | Buy |
395,000
+130,000
| +49% | +$1.71M | 1.91% | 23 |
|
|
2017
Q1 | $3.48M | Hold |
265,000
| – | – | 2.06% | 16 |
|
|
2016
Q4 | $3.43M | Buy |
265,000
+105,000
| +66% | +$1.62M | 2.83% | 13 |
|
|
2016
Q3 | $2.61M | Sell |
160,000
-19,029
| -11% | -$344K | 2.12% | 18 |
|
|
2016
Q2 | $2.22M | Sell |
179,029
-296,321
| -62% | -$3.7M | 2.21% | 16 |
|
|
2016
Q1 | $5.09M | Buy |
475,350
+71,478
| +18% | +$650K | 5.84% | 9 |
|
|
2015
Q4 | $5.92M | Buy |
+403,872
| New | +$4.94M | 5.23% | 8 |
|
Casdin Capital's MYOK Position: Q4 2020 in Review
Casdin Capital sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2020, closing a stake of 870,000 shares — an estimated $119M sold.
Casdin Capital first reported a position in MYOK in Q4 2015 and held it in 20 quarters. The position peaked at $119M in Q3 2020. 0 funds tracked by Wall St. Rank hold MYOK as of Q4 2020.
- Casdin Capital reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
- Casdin Capital sold 870,000 MyoKardia, Inc. Common Stock shares in Q4 2020, an estimated $119M.
- Casdin Capital first reported a position in MyoKardia, Inc. Common Stock in Q4 2015 and held it in 20 quarters.
- Casdin Capital's MyoKardia, Inc. Common Stock position peaked at $119M in Q3 2020.
- 0 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2020.
Based on Casdin Capital's 13F filing for Q4 2020, filed 16 Feb 2021.